Show simple item record

dc.contributor.authorCampbell, Jeffrey I.
dc.contributor.authorTabatneck, Mary
dc.contributor.authorSun, Mingwei
dc.contributor.authorHe, Wei
dc.contributor.authorMusinguzi, Nicholas
dc.contributor.authorHedt-Gauthier, Bethany
dc.contributor.authorLamb, Gabriella S.
dc.contributor.authorGoldmann, Don
dc.contributor.authorSabharwal, Vishakha
dc.contributor.authorSandora, Thomas J.
dc.contributor.authorHaberer, Jessica E.
dc.date.accessioned2023-08-22T09:59:30Z
dc.date.available2023-08-22T09:59:30Z
dc.date.issued2022
dc.identifier.citationCampbell, J. I., Tabatneck, M., Sun, M., He, W., Musinguzi, N., Hedt-Gauthier, B., ... & Haberer, J. E. (2022). Increasing Use Of Interferon Gamma Release Assays Among Children≥ 2 Years of Age in a Setting With Low Tuberculosis Prevalence. The Pediatric Infectious Disease Journal, 41(12), e534-e537.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/3089
dc.description.abstractUS guidelines recommend interferon gamma release assays (IGRAs) for diagnosis of tuberculosis infection in children. In this retrospective cohort study, IGRA use in children 2–17 years of age increased substantially between 2015–2021. Testing in inpatient/subspecialty settings (vs primary care), public (vs private) insurance, lower age, and non-English preferred language were associated with increased odds of receiving an IGRAen_US
dc.language.isoen_USen_US
dc.publisherThe Pediatric Infectious Disease Journalen_US
dc.subjectLatent tuberculosisen_US
dc.subjectTuberculinen_US
dc.subjectInterferon gamma release assayen_US
dc.subjectPediatricen_US
dc.titleIncreasing use of interferon gamma release assays among children ≥2 years of age in a setting with low tuberculosis prevalenceen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record